MiLaboratories, a US startup creating software solutions that redefine the parameters of biological research and development, has secured $10 million in Series A funding. Led by Kfund with participation from Speedinvest (which recently invested in Haaven and ContextSDK), Acrobator Ventures, Ten13, Somersault Ventures, EGB Capital, and Courtyard Ventures.
Expansion in the US market
The capital will be utilised to attract top-tier talent and expand into new markets, with a strategic emphasis on the United States.
This funding milestone comes alongside the launch of its Platforma.bio Software Development Kit (SDK), a revolutionary tool that streamlines and transforms how biologists build and deliver analytics and insights from next-generation sequencing data.
“Investing in platforms that bridge the gap between developers (in this case bioinformaticians) and business users (in this case biologists) is at the core of what we want to do in our fund. There is tremendous potential in democratising access to complex data enabling the delivery of immunological insights”, remarked Miguel Arias, General Partner of Kfund.
What issue does it address?
Biotech and pharmaceutical companies often face significant challenges when integrating next-generation sequencing (NGS) technology, particularly regarding computational infrastructure and scalability. One major issue is the biologists’ reliance on bioinformaticians to analyse the vast amounts of genomic data generated by NGS. Since bioinformatics requires specialised skills and computational resources, biologists frequently depend on overburdened bioinformatic teams, creating bottlenecks that delay research and actionable insights.
These challenges, along with data interoperability issues, high scaling costs, and the complexity of managing large datasets, further slow progress in drug discovery and research.
MiLaboratories overcomes these hurdles with its high-performance software platform that empowers biologists to analyse NGS data independently.
Frees up researchers for priority tasks
Led by CEO Stan Poslavsky, MiLaboratories provides an intuitive, scalable solution, which reduces the dependency on bioinformaticians, speeds up data processing, and integrates seamlessly with existing systems, accelerating research and fostering greater collaboration in genomics.
Platforma.bio offers a user-friendly, UI-centric design that simplifies the use of advanced computational biology tools, making them accessible to scientists without the steep learning curve of traditional systems.
Researchers can focus on their work while the platform automates resource management, data handling, and complex processes. The Platforma.bio Software Development Kit (SDK) is accessible from their open marketplace and is free for academic scientists, enabling them to develop custom analytical tools and applications. This approach enables researchers to tailor solutions to their specific needs.
“We believe that opening our platform to the developer community will accelerate the adoption of modern computational tools, setting the next level of biomedical research,” said Stan Poslavsky, CEO of MiLaboratories. “Today, therapy development is driven by data, algorithms, and AI. Our mission is to make cutting-edge computational advances accessible to researchers as they work towards discovering new drugs.”
Our thoughts on MiLaboratories
With a multi-billion dollar global market potential, MiLaboratories is poised to significantly disrupt the genomic research market. Furthermore, it will scale its operations in the coming years by focusing its efforts on attracting top-tier talent and expanding into the US market.
The post Speedinvest and others back MiLaboratories’ $10M round to revolutionise genome research appeared first on Tech Funding News.